Pharmapedia

Crack GPAT — Prepare for GPAT Online 
  • New Research finds ADHD Stimulant medications work in unexpected way
    26 December 2025

    New Research finds ADHD Stimulant medications work in unexpected way

    Researchers at Washington University School of Medicine in St. Louis suggest that common stimulant medications used to treat attention-deficit/hyperactivity disorder (ADHD), such as Ritalin and Adderall, may work in ways scientists didn’t previously understand. The findings challenge the long-held belief that these drugs primarily improve attention by acting directly on the brain’s attention circuits.

  • 19 December 2025
    Regulatory Harmonization and India’s Global Pharma Credibility

    In global pharmaceuticals, credibility is no longer conferred by capacity alone. It is earned— slowly, visibly, and irreversibly—through regulatory trust. As drug supply chains fragment, re- regionalize, and digitize, the decisive question for India’s pharmaceutical future is no longer how much we manufacture, but how seamlessly our regulatory systems align with the world we serve.

  • 18 December 2025
    Clues to Alzheimer’s disease may be hiding in our ‘junk’ DNA
    When most of us think of DNA, we have a vague idea it’s made up of genes that give us our physical features, our behavioural quirks, and keep our cells and organs running.
  • 8 December 2025
    Silicon chips on the brain : Researchers announce a new generation of brain-computer interface
    A new brain implant stands to transform human-computer interaction and expand treatment possibilities for neurological conditions such as epilepsy, spinal cord injury, ALS, stroke, and blindness – helping to manage seizures and restore motor, speech, and visual function. This is done by providing a minimally invasive, high-throughput information link directly to and from the brain.
  • 25 November 2025
    Scientists Discover “Two-Faced” Fat-Burning Enzyme That Controls Body’s Fat Storage From Inside the Nucleus
    In a breakthrough that reshapes our understanding of how the body manages fat, researchers have discovered that a well-known fat-burning enzyme, Hormone-Sensitive Lipase (HSL), has a second, unexpected job—acting inside the cell nucleus to regulate how fat cells grow, store energy, and function.
  • 25 November 2025
    Brain Enzyme OTULIN Emerges as a Surprising Master Switch in Tau Production - A New Frontier for Alzheimer’s Therapy
    Scientists have uncovered a previously unknown function of the enzyme OTULIN in regulating the production of tau, the protein that aggregates in neurodegenerative diseases such as Alzheimers.
  • 14 October 2025
    Cosmetics Stick
    In the ever-evolving world of cosmetics, stick formulations are rapidly gaining traction among beauty enthusiasts and professionals alike. These compact, travel-friendly products cater to the growing demand for convenient beauty routines, allowing for easy touch-ups and quick applications, especially during busy mornings.
  • 30 September 2025
    Why the Healthcare Rally is Gaining Momentum – The Story Behind the Numbers
    The healthcare and hospital stocks in India are experiencing unprecedented growth, surpassing mere survival to become key players in the stock market rally.
  • 25 September 2025
    India’s Global Capability Centres : The New Powerhouses of Pharma and Life Sciences

    Over the past two decades, Global Capability Centres (GCCs) in India have quietly transformed from back-office support units into central hubs of innovation and scientific expertise for some of the world’s biggest pharmaceutical and life sciences companies. Today, they are not only reducing costs for their parent organizations but also playing a decisive role in how new medicines are discovered, developed, tested, and delivered to patients worldwide.

  • 18 September 2025
    Pharma Giants Retreat from UK: A Looming Crisis for Life Sciences
    The United Kingdom, long considered a hub for pharmaceutical innovation, is facing an exodus of major pharmaceutical companies. Over the last several months, some of the industry biggest names, including Merck MSD, AstraZeneca, and Eli Lilly, have either cancelled or paused multi-million-pound projects
Subscribe to Pharmapedia